The integration and interpretation of pharmacogenomics – a comparative study between the United States of America and Europe: towards better health care

References

1. FDA/ICH. E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data, and sample coding categories. Guidance 2008;27:359–63.10.1089/blr.2008.9943Search in Google Scholar

2. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci 2000;2:E4.10.1208/ps020104Search in Google Scholar

3. Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010;429:435–49.10.1042/BJ20100522Search in Google Scholar

4. Vogel F. Moderne problem der Humangenetik. Ergeb Inn Med Kinderheilkd 1959;12:52–125.10.1007/978-3-642-94744-5_2Search in Google Scholar

5. Tarlov AR, Brewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med 1962;109:209–34.10.1001/archinte.1962.03620140081013Search in Google Scholar

6. Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. Science 1968;159:1479–80.10.1126/science.159.3822.1479Search in Google Scholar

7. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442–6.10.1038/331442a0Search in Google Scholar

8. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990;265:17209–14.10.1016/S0021-9258(17)44890-3Search in Google Scholar

9. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001;22:298–305.10.1016/S0165-6147(00)01717-XSearch in Google Scholar

10. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med 2011;5:795–806.10.2217/bmm.11.94Search in Google Scholar PubMed PubMed Central

11. Vesell ES. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 2000;40:930–8.10.1177/00912700022009666Search in Google Scholar PubMed

12. Motulsky AG, Qi M. Pharmacogenetics, pharmacogenomics and ecogenetics. J Zhejiang Univ Sci B 2006;7:169–70.10.1631/jzus.2006.B0169Search in Google Scholar PubMed PubMed Central

13. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 2010;4:278–81.10.1186/1479-7364-4-4-278Search in Google Scholar PubMed PubMed Central

14. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011;89:464–7.10.1038/clpt.2010.279Search in Google Scholar PubMed PubMed Central

15. GenomeWeb Staff Reporter. Personalis Licenses PharmGKB Database, Launches Genomic Services [Internet]. GenomeWeb. [cited 2015 Nov 27]. Available at: http://www.genomeweb.com/informatics/personalis-licenses-pharmgkb-database-launches-genomic-services.Search in Google Scholar

16. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling [Internet]. [cited 2015 Nov 29]. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.Search in Google Scholar

17. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015;526:343–50.10.1038/nature15817Search in Google Scholar PubMed PubMed Central

18. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med 2011;13:987–95.10.1097/GIM.0b013e318238b38cSearch in Google Scholar PubMed PubMed Central

19. Coleman H, Ashcraft K. Genelex Corporation. Pharmacogenomics 2008. p. 469–75.10.2217/14622416.9.4.469Search in Google Scholar PubMed

20. European Medicines Agency. Mandate, objectives and rules of procedure for the CHMP PG Working Party [Internet]. 2009 [cited 2015 Nov 29]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500069715.pdf.Search in Google Scholar

21. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 2008;83:781–7.10.1038/sj.clpt.6100507Search in Google Scholar PubMed

22. Hall I. Conference scene: UK pharmacogenetics and stratified medicine network. Pharmacogenomics 2012;13:19–20.10.2217/pgs.11.162Search in Google Scholar PubMed

23. Manolopoulos VG, Dechairo B, Huriez A, Kühn A, Llerena A, van Schaik RH, et al. Pharmacogenomics and personalized medicine in clinical practice. Pharmacogenomics 2011;12:597–610.10.2217/pgs.11.14Search in Google Scholar PubMed

24. Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J 2015;15:201–10.10.1038/tpj.2014.86Search in Google Scholar PubMed

25. Prasad K, Breckenridge A. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives. Drug Discov Today 2011;16:867–72.10.1016/j.drudis.2011.08.016Search in Google Scholar PubMed

26. Maliepaard M, Nofziger C, Papaluca M, Zineh I, Uyama Y, Prasad K, et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov 2013;12:103–15.10.1038/nrd3931Search in Google Scholar PubMed

27. European Medicines Agency. Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products [Internet]. [cited 2015 Nov 29]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500121954.pdf#EMA pharmacogenetic guideline for pharma%28pdf%29.Search in Google Scholar

28. European Medicines Agency. Pharmacogenomics Working Party [Internet]. [cited 2015 Nov 29]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_listing_000018.jsp&mid=WC0b01ac0580028d91.Search in Google Scholar

29. Higgs J, Gambhir N, Ramsden SC, Poulton K, Newman WG. Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. Genet Test Mol Biomarkers 2010;14:121–5.10.1089/gtmb.2009.0156Search in Google Scholar PubMed

30. Kollek R, van Aken J, Feuerstein G, Schmedders M. Pharmacogenetics, adverse drug reactions and public health. Community Genet 2006;9:50–4.10.1159/000090693Search in Google Scholar PubMed

31. Shalala D. Protecting research subjects – what must be done. New Engl J Med 2000;343:808–10.10.1056/NEJM200009143431112Search in Google Scholar PubMed

32. Fleuren M, Wiefferink K, Paulussen T. Determinants of innovation within health care organizations: literature review and Delphi study. Int J Qual Health Care 2004;16:107–23.10.1093/intqhc/mzh030Search in Google Scholar PubMed

33. Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007;32:187–95.10.1111/j.1365-2710.2007.00805.xSearch in Google Scholar PubMed

34. The Royal Society. Personalised medicines: hopes and realities [Internet]. [cited 2015 Nov 25]. Available at: https://royalsociety.org/∼/media/Royal_Society_Content/policy/publications/2005/9631.pdf.Search in Google Scholar

35. Haga SB, O’Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J 2012;12:197–204.10.1038/tpj.2011.1Search in Google Scholar PubMed PubMed Central

36. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012;91:450–8.10.1038/clpt.2011.306Search in Google Scholar PubMed

37. Dodson C, Van Riper M. Analysis of clinicians’ attitudes towards pharmacogenomics. Per Med 2011;8:533–40.10.2217/pme.11.43Search in Google Scholar PubMed

38. Hedgecoe AM. Context, ethics and pharmacogenetics. Stud Hist Philos Sci Part C Stud Hist Philos Biol Biomed Sci 2006;37:566–82.10.1016/j.shpsc.2006.06.003Search in Google Scholar PubMed

39. Bartlett MJ, Green DW, Shephard EA. Pharmacogenetic testing in the UK clinical setting. Lancet 2013;381:1903.10.1016/S0140-6736(13)61160-5Search in Google Scholar

40. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. J Am Med Assoc 2003;289:1107–16.10.1001/jama.289.9.1107Search in Google Scholar

41. United Health. Personalized medicine: trends and prospects for the new science of genetic testing and molecular diagnostics [Internet]. [cited 2015 Nov 29]. Available at: http://www.unitedhealthgroup.com/∼/media/uhg/pdf/2012/unh-working-paper-7.ashx.Search in Google Scholar

42. Powell KP, Cogswell WA, Christianson CA, Dave G, Verma A, Eubanks S, et al. Primary care physicians’ awareness, experience and opinions of direct-to-consumer genetic testing. J Genet Couns 2012;21:113–26.10.1007/s10897-011-9390-9Search in Google Scholar

43. Fears R, ter Meulen V. The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 2013;21:703–7.10.1038/ejhg.2012.238Search in Google Scholar

44. Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012;92:563–6.10.1038/clpt.2012.140Search in Google Scholar

45. O’Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012;92:446–9.10.1038/clpt.2012.117Search in Google Scholar

46. Peterson JF, Bowton E, Field JR, Beller M, Mitchell J, Schildcrout J, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med 2013;15:833–41.10.1038/gim.2013.109Search in Google Scholar

47. Ullman-Cullere MH, Mathew JP. Emerging landscape of genomics in the Electronic Health Record for personalized medicine. Hum Mutat 2011;32:512–6.10.1002/humu.21456Search in Google Scholar

48. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012;379:1705–11.10.1016/S0140-6736(12)60161-5Search in Google Scholar

49. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012;92:87–95.10.1038/clpt.2011.371Search in Google Scholar PubMed PubMed Central

50. Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther 2014;95:423–31.10.1038/clpt.2013.229Search in Google Scholar PubMed PubMed Central

51. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol 2015;55:89–106.10.1146/annurev-pharmtox-010814-124835Search in Google Scholar PubMed PubMed Central

52. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther 2011;89:662–73.10.1038/clpt.2011.34Search in Google Scholar PubMed

53. Samwald M. Positive evaluation of U-PGx proposal! [Internet]. U-PGx. [cited 2015 Nov 29]. Available at: http://upgx.eu/?p=158.Search in Google Scholar

54. Welch BM, Kawamoto K. Clinical decision support for genetically guided personalized medicine: a systematic review. J Am Med Informatics Assoc 2012;20:388–400.10.1136/amiajnl-2012-000892Search in Google Scholar PubMed PubMed Central

55. Crews KR, Hicks JK, Pui C-H, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012;92:467–75.10.1038/clpt.2012.120Search in Google Scholar PubMed PubMed Central

56. Huckvale C, Car J, Akiyama M, Jaafar S, Khoja T, Bin Khalid A, et al. Information technology for patient safety. Qual Saf Health Care 2010;19(Suppl 2):i25–33.10.1136/qshc.2009.038497Search in Google Scholar PubMed

57. Nanji KC, Slight SP, Seger DL, Cho I, Fiskio JM, Redden LM, et al. Overrides of medication-related clinical decision support alerts in outpatients. J Am Med Inform Assoc 2014;21:487–91.10.1136/amiajnl-2013-001813Search in Google Scholar PubMed PubMed Central

58. Cresswell K, Coleman J, Slee A, Morrison Z, Sheikh A. A toolkit to support the implementation of electronic prescribing systems into UK hospitals: preliminary recommendations. J R Soc Med 2014;107:8–13.10.1177/0141076813502955Search in Google Scholar PubMed PubMed Central

59. Genomics England. Genomics England launched, mapping DNA to better understand cancer, rare and infectious diseases [Internet]. [cited 2015 Nov 29]. Available at: http://www.genomicsengland.co.uk/genomics-england-launch/.Search in Google Scholar

60. Harrison MB, Graham ID, van den Hoek J, Dogherty EJ, Carley ME, Angus V. Guideline adaptation and implementation planning: a prospective observational study. Implement Sci 2013;8:49.10.1186/1748-5908-8-49Search in Google Scholar PubMed PubMed Central